Tissue Regenix Group (TRX)
TRX Share PerformanceMore
|52 week high||16.750 02/05/17|
|52 week low||5.500 08/12/17|
|52 week change||-5.000 (-31.25%)|
|4 week volume||3,936,556 31/03/18|
Latest News« previous» nextMore
24/04/2018 - 07:00 RNS
RNS Number: 8532L Tissue Regenix Group PLC 24 April 2018 Tissue Regenix Group plc Successful completion of technical transfer for DermaPure manufacturing at CellRight Facility First product sales from inhouse manufacturing Leeds, 24 April 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices compan...
19/04/2018 - 15:29 RNS
RNS Number: 5146L Tissue Regenix Group PLC 19 April 2018 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii: Tissue Regeni...
05/04/2018 - 07:15 RNS
Hardman & Co Hardman & Co Research: Tissue Regenix (TRX): CellRight hits the right note 05-Apr-2018 / 07:15 GMT/BST Hardman & Co Research: CellRight hits the right note CellRight hits the right note - Tissue Regenix (TRX) has a broad portfolio of regenerative medicine products for the biosurgery, orthopaedics, dental and cardiac markets. The company has tw...
26/03/2018 - 07:00 RNS
RNS Number: 8422I Tissue Regenix Group PLC 26 March 2018 Tissue Regenix Group plc Annual results for period ended 31 December 2017 Group Revenues increase to 5.2m Acquisition of CellRight Technologies completed Significant commercial agreements signed Leeds, 26 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regen...
16/03/2018 - 16:40 RNS
RNS Number: 0406I Tissue Regenix Group PLC 16 March 2018 Tissue Regenix Group plc Publication of Financial Results Leeds, 16 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company announces that the audit process of its annual financial statements is still ongoing and the audited results for ye...
08/03/2018 - 08:15 RNS
RNS Number: 0429H Tissue Regenix Group PLC 08 March 2018 Hardman & Co: Full-year 2017 - what to look for Full-year 2017: what to look for - TRX has a broad portfolio of regenerative medicine products developed from decellularised human and porcine soft tissues for the wound care, orthopaedics, and cardiac markets. Since the launch of DermaPure, focus ha...
06/03/2018 - 08:00 RNS
RNS Number: 7649G Tissue Regenix Group PLC 06 March 2018 Tissue Regenix Group plc CellRight Technologies signs multi-year distribution agreement with Arthrex, Inc. Leeds, 06 March 2018 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Group") the regenerative medical devices company today announces subsidiary CellRight Technologies ("CellR...
26/02/2018 - 10:33 StockMarketWire
Regenerative medical devices company Tissue Regenix Group said it had entered into an exclusive distribution partnership...
|Dividend yield||0 %|
Latest discussion posts More
“Manufacturing of DermaPure established in CellRight facility ....see RNS. Perhaps profitability is nearer than you think TP”▼
“Woodford now 26% TP”▼
“Two RNSs have been issued recently... Finals on 26/03 and Hardman Research paper 5/04. Both make interesting reading and indicate that the company is making better progress ...”▼
Codes & Symbols
|Symbols||TRX, LSE:TRX, TRX.L, TRX:LN, LON:TRX, XLON:TRX|